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Abstract
Background: Although cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene, the severity of disease is highly variable indicating the influence
of modifier genes. The intestines of Cftr  deficient mice (CF mice: Cftrtm1Unc) are prone to
obstruction by excessive mucus accumulation and are used as a model of meconium ileus and distal
intestinal obstruction syndrome. This phenotype is strongly dependent on the genetic background
of the mice. On the C57Bl/6 background, the majority of CF mice cannot survive on solid mouse
chow, have inflammation of the small intestine, and are about 30% smaller than wild type
littermates. In this work potential modifier loci of the CF intestinal phenotype were identified.
Results: CF mice on a mixed genetic background (95% C57Bl/6 and 5% 129Sv) were compared to
CF mice congenic on the C57Bl/6 background for several parameters of the intestinal CF
phenotype. CF mice on the mixed background exhibit significantly greater survival when fed dry
mouse chow, have reduced intestinal inflammation as measured by quantitative RT-PCR for marker
genes, have near normal body weight gain, and have reduced mucus accumulation in the intestinal
crypts. There was an indication of a gender effect for body weight gain: males did not show a
significant improvement at 4 weeks of age, but were of normal weight at 8 weeks, while females
showed improvement at both 4 and 8 weeks. By a preliminary genome-wide PCR allele scanning,
three regions were found to be potentially associated with the milder phenotype. One on chr.1,
defined by marker D1Mit36, one on chr. 9 defined by marker D9Mit90, and one on chr. 10, defined
by marker D10Mit14.
Conclusion:  Potential modifier regions were found that have a positive impact on the
inflammatory phenotype of the CF mouse small intestine and animal survival. Identification of
polymorphisms in specific genes in these regions should provide important new information about
genetic modifiers of the CF intestinal phenotype.
Background
Cystic fibrosis (CF) is caused by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR)
gene [1]. Different mutations have a range of effects on
the levels of CFTR protein and its proper functioning in
epithelial transport of Cl- and HCO3
- [2,3]. The severity of
the pancreatic phenotype in human CF is well correlated
with the extent of impaired CFTR function caused by spe-
cific mutations. Loss of CFTR function results in destruc-
tion of the exocrine tissue and eventual pancreatic
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insufficiency. On the other hand, the effects of CF on
organs including the airways and intestines is less well
correlated with specific CFTR mutations and their effects
on CFTR protein function [4-8]. This indicates that other
genes are likely to be important as modifiers of the CF
phenotype.
With the exception of pancreatic insufficiency resulting in
impaired digestion, other aspects of CF are less readily
related to loss of CFTR function. Nutritional problems can
persist even with adequate oral enzyme supplementation
[9] and neutralization of gastric acid to improve lipase
function [10], and may involve both impaired digestion
and absorption of nutrients [11]. Inadequate absorption
or assimilation of nutrients appears to be of greater
importance because even with adequate oral enzyme sup-
plementation nutrition is rarely fully corrected [11]. There
is also excessive mucus accumulation in the CF intestine,
and inappropriate inflammation is common [12]. Mucus
is involved in obstruction of the gut which occurs fre-
quently in CF infants (called meconium ileus, MI) and
adults (called distal intestinal obstruction syndrome,
DIOS) [11,13]. And, similar to CF airways, there is also an
inflammation of the CF intestines [14,15]. These changes
are less directly related to specific mutations in the CFTR
gene and are likely related to other differences in individ-
ual genetic makeup.
Previous work using human patients and genetically
altered mice has identified some modifier genes and have
advanced our understanding of CF pathophysiology [4].
In one study using CF mice on different genetic back-
grounds, a region on mouse chromosome 7 was shown to
ameliorate intestinal blockage and the effect was in part
due to a calcium-regulated Cl-channel which compen-
sated for loss of CFTR function [16,17]. Marker haplo-
types of the syntenic region of human chromosome
19q13 were also shown to be associated with the risk of
MI in CF patients [18]. In other work, a region on mouse
chr. 6 was strongly associated with lung inflammation,
consisting of mononuclear cell interstitial infiltration and
fibrosis in CF mouse airways; and other loci on chr. 1, 2,
10, and 17 were also linked to the airway phenotype [19].
In this work, CF mice on a mixed strain background were
found to have a less severe CF phenotype compared to CF
mice congenic on the C57Bl/6 background. There were no
differences in the pancreatic phenotype comparing CF
mice on the different backgrounds [20]. However, mice
on the mixed background seemed more robust than CF
mice on the B6 background which prompted us to charac-
terize them in greater detail. Genome wide allele scanning
was used to begin identification of regions associated with
the less severe intestinal phenotype. Future identification
of specific genes should further our understanding of the
complex intestinal CF phenotype.
Results and discussion
CF mice on the mixed background have improved body 
weight gain
Body mass was recorded for male and female mice at 4
and 8 weeks of age. On the B6 background, female and
male mice are about 30% smaller than wild type mice at
both 4 and 8 weeks of age (Fig. 1A, B). By comparison,
female CF mice on the mixed background were not signif-
icantly smaller than wild type mice at 4 weeks of age (Fig.
1A). The improved body weight of female CF mice on the
mixed background was maintained at 8 weeks of age.
Male CF mice on the mixed background at 4 weeks of age
were significantly smaller than wild type and not signifi-
cantly larger than CF mice congenic on the B6 background
(Fig. 1B). By 8 weeks of age, CF males on the mixed back-
ground were 12% smaller but this was not significantly
different compared to wild type mice (Fig. 1B).
CF mice on the mixed background have reduced 
expression of inflammatory markers
Previous work showed that CF mice on the B6 back-
ground have an innate-type inflammation of the small
intestine [21]. To determine whether the mixed genetic
background affected expression of inflammatory marker
genes, quantitative, real-time RT-PCR was used to meas-
ure gene expression. Expression of the following genes
was compared in wild type and CF mice on the different
genetic backgrounds. Mast cell protease 2 (Mcpt2) is a
marker of differentiated mast cells [22] and mast cells are
more abundant in the B6 CF mouse intestine. Leucine-
rich α 2 glycoprotein (Lrg1, [23]) is a marker of differenti-
ating neutrophils, which are more numerous in the B6 CF
mouse intestine. The same gene is also known as leucine-
rich high endothelial cell glycoprotein (Lrhg) and has
been shown to be a marker of high endothelial venules
(HEV) [24] which increase in tissues during inflammation
[25,26]. Hematopoietic cell transcript 1 (HemT1, [27]) is
a marker of blood cell proliferation and its expression is
strongly elevated in the B6 CF mouse small intestine.
Serum amyloid A3 (SAA3, [28]) is an acute phase gene
and its expression in villus epithelial cells is increased in
the B6 CF intestine. Suppressor of cytokine signaling 3
(SOCS3, [29]) is an anti-inflammatory gene that interacts
with the JAK-STAT pathway and its expression in
increased in the B6 CF intestine. Muclin (also known as
dmbt1, [30]) expression is upregulated in the B6 CF intes-
tine; it is a cell surface glycoprotein postulated to be an
epithelial protective molecule [21,31].
Consistent with previous results, Mcpt2 was increased in
CF mice on the B6 background by over 9-fold compared
to wild type (Fig. 2A). By contrast, there was not aBMC Genetics 2005, 6:29 http://www.biomedcentral.com/1471-2156/6/29
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significant difference in Mcpt2 expression between CF and
wild type on the mixed background (Fig. 2A). Lrg1/Lrhg
expression was increased more than 20-fold in CF mice on
the B6 background compared to wild type, but there was
no significant difference between CF and wild type on the
mixed background (Fig. 2B). SAA3 mRNA was about 3.5-
fold increased in CF mice on the B6 background, but was
not significantly different compared to wild type on the
mixed background (Fig. 2C). SOCS3 was more than 2-
fold increased in CF mice on the B6 background com-
pared to wild type, and on the mixed background was
only 1.5-fold greater than wild type, and the difference
was not significant (Fig. 2D). Muclin  is overexpressed
almost 3-fold in the CF intestine on the B6 background,
but on the mixed background the expression level in CF
mice was not significantly different than wild type (Fig.
2E). Finally, HemT1 was overexpressed almost 20-fold in
B6 CF mice compared to wild type, and on the mixed
background the CF expression level was not statistically
different from wild type (Fig. 2F).
Because of the gender differences in body weight, the gene
expression data were analyzed by gender but there was no
significant difference between females and males. With
the limited number of animals, there was also no evidence
for imprinting.
CF mice on the mixed background have less intestinal 
mucus accumulation
The most striking histological difference in the CF mouse
small intestine is the accumulation of mucus in intestinal
crypts which is associated with the lethal obstruction that
results in death of these mice on a standard solid chow
diet [32]. Using periodic acid Schiff's staining for neutral
mucins, histological analysis of small intestine tissues was
performed. The wild type small intestine on both the B6
and the mixed genetic backgrounds were similar. The
intestinal crypts were very small with only traces of PAS-
reactivity in the lumen (Fig. 3A and 3C, respectively). The
surfaces of the villus epithelium were moderately stained
and goblet cells were strongly stained in the wild type tis-
sues. In contrast, the intestine of CF mice on the B6
genetic background exhibited greatly dilated crypts filled
with PAS-reactive mucus (Fig. 3B). CF mice on the mixed
background had less mucus accumulation than CF mice
on the B6 background (Fig. 3D-F). The amount of mucus
in CF mice on the mixed background was variable from
mouse to mouse. In some mice (Fig. 3D), only occasional
crypts had accumulated mucus and the crypt lumina were
not very dilated. In some mice there was more mucus in
the crypts (Fig. 3E), while others had moderate mucus
accumulation (Fig. 3F). A total of six CF mice on the
mixed background were examined histologically, and
Effect of genetic background on body weights of CF mice Figure 1
Effect of genetic background on body weights of CF mice. (A) Female and (B) male mice were weighed at 4 and 8 weeks of age. 
Data are means ± SEM. (*) P < 0.001 vs other three groups by ANOVA with a post-hoc Tukey's test. There were no significant 
differences for any of the other comparisons. Data were obtained from: 65 wild type and 26 CF B6 females, 36 wild type and 8 
CF mixed background females, 68 wild type and 30 CF B6 males, and 37 wild type and 6 CF mixed background males.BMC Genetics 2005, 6:29 http://www.biomedcentral.com/1471-2156/6/29
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three had little mucus, one had some mucus, and two had
moderate amounts of mucus. Despite the variability, all
the CF mice on the mixed background had less crypt dila-
tion and less mucus accumulation compared to CF mice
on the B6 background.
Thus, it appears that whatever the nature of the genetic
differences between the two background strains, they
affect secretion and accumulation of mucus in the CF
small intestine. To determine if the difference could be
accounted for by altered mucin gene expression,
Effect of genetic background on inflammatory gene expression in CF mouse small intestine Figure 2
Effect of genetic background on inflammatory gene expression in CF mouse small intestine. RNA expression levels were determined 
by quantitative real-time RT-PCR using gene-specific primers. Data are expressed relative to GAPDH mRNA, which does not 
vary between wild type and CF mice. Data are means ± SEM. (*) CF vs wild type on the B6 background, P < 0.005; (+) CF on 
the mixed background vs CF on the B6 background, P < 0.05 by ANOVA with a post-hoc Tukey's test. There were no signifi-
cant differences for any of the 6 genes comparing: wild type B6 mice vs wild type mixed background; or CF mice on the mixed 
background vs wild type on either background. There were 8–11 samples analyzed per group for each gene.BMC Genetics 2005, 6:29 http://www.biomedcentral.com/1471-2156/6/29
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Histological appearance of the small intestine of wild type and CF mice on the different genetic backgrounds Figure 3
Histological appearance of the small intestine of wild type and CF mice on the different genetic backgrounds. Tissue was paraffin 
embedded and stained with PAS for neutral mucins. The sections are from the middle portion of the small intestine (A) Wild 
type on the B6 background. (B) CF on the B6 background. (C) Wild type on the mixed background. (D-F) CF on the mixed 
background. (A, C) In the wild type tissue from both backgrounds, the crypts are small and have narrow lumina (arrows). (B) In 
the CF tissue on the B6 background, the crypt lumina are greatly dilated and filled with PAS-reactive mucus (arrows). In some 
CF mice on the mixed background, the crypts are not apparently different than wild type (D), and the crypts are normal 
appearing (arrows). Some CF mice on the mixed background had mildly affected crypts (E), while others had greater crypt dila-
tion and mucus accumulation (F). Overall, the CF mice on the mixed background were less severely affected compared to 
those on the B6 background.BMC Genetics 2005, 6:29 http://www.biomedcentral.com/1471-2156/6/29
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quantitative RT-PCR was used to measure mRNA expres-
sion of the intestinal goblet cell mucin gene, Muc2. In wild
type intestine, B6 mice had 0.079 +/- 0.024 copies of
Muc2/GAPDH (n = 8), and on the mixed background the
level was 0.077 +/- 0.012 (n = 11). CF mice on the B6
background had 0.059 +/- 0.024 copies of Muc2 mRNA
per GAPDH (n = 11), and on the mixed background the
level was 0.056 +/- 0.010 (n = 11). Despite the increased
mucus accumulation in CF, there is a slight decrease in
Muc2 mRNA in the CF small intestine (P < 0.0001), as pre-
viously reported [33]. However, the milder CF phenotype
on the mixed background, which includes less mucus
accumulation, does not involve decreased mucin gene
expression.
CF mice on the mixed background have improved survival
As reported by others [34], the expected number of Cftr
null mice on the B6 background that survived to weaning
was significantly less than that expected from Mendelian
genetics (Tables 1 and 2). The degree of significance was
greater for male mice (Tables 1 and 2). In contrast, on the
mixed background, the distribution of genotypes of
female offspring was not significantly different from the
expected (Tables 1). For male mice on the mixed back-
ground, the P-value was less significant but still different
compared to the B6 males (Table 2). These data indicate
that the mixed background is associated with increased
survival of CF mice.
The major cause of death in CF mice is intestinal obstruc-
tion, and intestinal obstruction is worsened when the
mice are fed standard solid mouse chow [35]. Since the CF
mice on the mixed background had better weight gain
than on the B6 background and less mucus accumulation
in the small intestine, their ability to survive on solid
chow was tested. Mice were maintained on the liquid diet
until 8 weeks of age, and then switched to solid chow for
up to eight weeks. As shown in Fig. 4, wild type mice had
100% survival on chow, as expected. The majority of CF
mice on the B6 background died within 2–3 weeks on
solid chow, with about 60% mortality over the 8 week
period. In contrast, only 22% of the CF mice on the mixed
background died (Fig. 4).
Identification of potential modifier loci
To determine the contributions of B6 and 129 alleles to
the mixed genetic background, and to identify potential
modifier regions, tail DNA was analyzed by PCR for mark-
ers of polymorphisms between these two mouse strains.
Mice congenic on the B6 background, which were derived
from mice originally on a B6/129 mixed background,
were also analyzed to confirm they are congenic B6.
Twelve CF mice on the B6 background averaged 99.5% B6
alleles. One of the twelve mice had alleles from both
strains at chr.9, 40 cM. All twelve mice had both B6 and
129 markers on chromosome 6, 1 cM which is probably
due to the targeted Cftr gene which is at chr.6, 3.1 cM [36].
Table 1: Distribution of Cftr genotypes in female offspring from breeding Cftr heterozygotes on the B6 and mixed backgrounds.
B6 Background Mixed Background
Cftr Observed Expected Observed Expected
+/+ 207 175 57 47
+/- 371 350 88 94
-/- 122 175 42 47
P 0.00001 (0.04533)* 0.21724
Statistical analysis was by Chi-square. (*) P-value if the sample size for the B6 mice is adjusted to be equal to that of the mixed background mice, 
assuming the same distribution of genotypes.
Table 2: Distribution of Cftr genotypes in male offspring from breeding Cftr heterozygotes on the B6 and mixed backgrounds.
B6 Background Mixed Background
Cftr Observed Expected Observed Expected
+/+ 240 201 57 52
+/- 431 403 115 104
-/- 134 201 36 52
P <0.00001 (0.01612)* 0.03749
Statistical analysis was by Chi-square. (*) P-value if the sample size for the B6 mice is adjusted to be equal to that of the mixed background mice, 
assuming the same distribution of genotypes.BMC Genetics 2005, 6:29 http://www.biomedcentral.com/1471-2156/6/29
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Three CF mice on the mixed background were initially
analyzed and were found to be 95% B6, 5% 129. A second
group of 8 CF mice was analyzed and the markers used
were refined to focus on the chromosomal regions show-
ing variations from the B6 strain. The differences found
from the two analyses are combined in Table 3. The differ-
ences in the mixed strain CF mice were at chr.1, 92 cM (9
of 11 mice had both B6 and 129 alleles); chr.9, 9 cM (all
11 mice had two 129 alleles); and chr.10, 65 cM (10 mice
had both B6 and 129 alleles).
Because the spacing of markers used was about 12 cM,
genes within 75% of this interval on either side of the
markers were looked at for potential relevance to the
milder CF intestinal phenotype. None of the known chlo-
ride channels that might substitute for the missing CFTR
are in the regions of the three chromosomes associated
with the milder phenotype. There are several potassium
channel genes in the identified regions that potentially
could affect electrolyte and fluid transport: Kcnj9 (chr.1,
94.2 cM), Kcnj10 (chr.1, 93.5 cM), Kcnj5 (chr.9, 11 cM),
and Kcnc2 (chr.10, 62 cM). All gene names are from the
Mouse Genome Informatics website http://www.infor
matics.jax.org.
Inflammation is a hallmark of CF, and whether there is an
inherent defect in CF that predisposes to excessive inflam-
mation is controversial. Several genes involved in inflam-
mation and the immune system are located in the regions
of the markers identified: TNF superfamily members
Tnfsf4, 6, and 8 (chr.1, 84.9–85 cM) which are involved in
T cell activation [37,38]; three selectin genes (Sele, Sell,
Selp, chr.1, 86.6 cM) which are involved in immune cell
infiltration into inflamed tissues [39]; several members of
immune cell surface proteins of the Slam family (slamf1,
2, 5, 6, and 9; chr.1, 89.5–93.3 cM) [40]; the chemokine
gene Xcl1 (chr.1, 87 cM) which is expressed by mast cells
and recruits lymphocytes [41]; several immunoglobulin
Fc receptor genes (Fcrl3, Fcgr2b, and Fcgr3 at chr.1, 92.3
Table 3: Genome scanning analysis of CF mice on the mixed background.
Chromosome cM B6/B6 129/129 B6/129 Number of Mice
19 22 0 91 1
1 1 0 2 326 1 1
272013
990 1 1 0 1 1
92 08 1 1 1 1 *
9 3 3 5038
9 4 0 1113
1 0 4 0 6028
10 65 0 1 10 11
1 1 3 5 5038
11 43 6 0 5 11
1 2 1 9 6028
The table shows the distribution of B6 and 129 alleles in mice from the two genetic backgrounds. An initial analysis was performed on 3 samples 
and a second analysis on 8 more samples. Only the markers that were not uniformly B6 alleles are shown. Some of the markers were refined based 
on the initial analysis, so not all markers were used for all 11 mice. (*) Eleven samples were analyzed but one sample was ambiguous.
Effect of genetic background on CF mouse survival on solid  chow Figure 4
Effect of genetic background on CF mouse survival on solid chow. 
Mice were maintained on the liquid diet (Peptamen) until 8 
weeks of age, at which time they were fed standard solid 
mouse chow for up to 8 additional weeks. Deaths were 
recorded as they occurred and mice in obvious distress were 
sacrificed and 'death' recorded as the subsequent day. By log-
rank test, CF mice on the mixed background had significantly 
earlier death compared to wild type (P = 0.035), and signifi-
cantly later death than CF mice on the B6 background (P = 
0.025). CF mice on the B6 background also died significantly 
earlier than wild type (P < 0.0005).BMC Genetics 2005, 6:29 http://www.biomedcentral.com/1471-2156/6/29
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cM; Fcer1g at chr.1, 93.3 cM; Fcer1a at chr.1, 94.2 cM); the
flagellin receptor Tlr5 (chr.1, 98 cM); Mmp3 (chr.9, 1 cM)
which recruits CD4+ lymphocytes [42]; Mmp7 (chr.9, 1
cM) which activates Paneth cell-derived cryptdins (α -
defensins) [43]; Icam1 (chr.9, 7 cM) which is involved in
lymphocyte infiltration into inflamed tissues [44]; Kitl
(chr.10, 57 cM) which is also known as stem cell factor,
and is crucial for mast cell differentiation [45]; Im5
(chr.10, 65 cM) which is involved in antibody-responsive-
ness [46]; Lyzs (chr.10, 66 cM) which is a Paneth cell prod-
uct that digests cell walls of bacteria [47]; Ifng (chr.10, 67
cM) which is an important inflammatory signal in CF as
well as other conditions [48]; Il22  (chr.10, 67 cM), a
member of the anti-inflammatory IL-10 interleukin fam-
ily [49]; and the Stat2 and 6 genes (chr.10, 70 cM) which
are important components of intracellular signaling path-
ways [50].
Also near the identified markers are a number of QTL
associated with body weight: Cfbw1, CF mouse body
weight at chr.1, 85 cM; Obq9, obesity 9 at chr.1, 88 cM;
Bw8q1, body weight 8 at chr.1, 100 cM; Lbm6, lean body
mass 6 at chr.9, 7.7 cM; Bwtq4, body weight 4 at chr.9, 8
cM; Bgeq8, body growth early 8 at chr.10, 57 cM; and
Pbwg5, postnatal body weight growth 5 at chr.10, 68 cM.
Clearly, there are numerous genes in the three regions
identified in this study. Because the CF mouse intestinal
phenotype is characterized by an innate type immune
response, with increases in mast cells and neutrophils, the
genes that affect these cells are of special interest. The Kitl
gene is crucial for differentiation of mast cells, and CF
mice on the mixed background have much fewer mature
mast cells than on the B6 background as revealed by less
expression of Mcpt2. Similarly, for neutrophils the
selectins and Icam1 are of interest, as these proteins are
required for extravasation of neutrophils from the circula-
tion into the inflamed tissue.
Altered immune responses may also relate to excessive
mucus accumulation in the CF intestine. It is unclear why
mucus accumulates to high levels in CF tissues. In part it
may be due to reduced fluid secretion and a more acidic
environment in the lumina of affected organs. However,
there is also evidence for hypersecretion of mucus in CF
[12], and it is likely that effector molecules released by
mast cells and neutrophils (histamine, proteases, prostag-
landins) have an important role in stimulating mucus
secretion.
Conclusion
This work demonstrated that the CF inflammatory pheno-
type is much less severe in mice with a small contribution
of 129/Sv alleles. A preliminary analysis identified regions
on chr.1, 9, and 10 are that are potentially associated with
the milder phenotype. Because of the inflammation of the
CF small intestine, and the possible effects of immune
cells on mucus secretion, the genes in the identified
regions which are involved in mast cell and neutrophil
differentiation and behavior are of special interest as
potential CF modifiers. Future work should focus on nar-
rowing down these regions and determining if there are
polymorphisms that affect expression of specific genes
that make the CF intestinal phenotype less severe.
Methods
Animals
Wild type and Cftr  null mice on two different genetic
backgrounds were used in this study. One group was con-
genic on the C57Bl/6 (B6) background, as previously
described [21]. The other group was on a mixed back-
ground of about 95% B6 and 5% 129/Sv (129). The mice
on the mixed background originated as part of a recently
published study [20] as follows. Mice carrying a targeted
mutation of the gastrin gene on a mixed B6/129 back-
ground [51] were bred for eight generations onto the B6
background. The gastrin(+/-) mice were then crossed for
six generations with Cftr(+/-) mice congenic on the B6
background. A genome scan at this point showed that the
mice were about 95% B6 and 5% 129 (see below). These
mice were bred to obtain mice wild type for both gastrin
alleles and either Cftr homozygous wild type [Cftr(+/+)]
or Cftr homozygous null [Cftr(-/-)].
Mice were genotyped at 2 weeks of age by PCR as previ-
ously described [21]. Unless otherwise stated, mice were
maintained on a complete elemental liquid diet (Pepta-
men; Nestle Deerfield, IL) to prevent intestinal obstruc-
tion that occurs in CF mice [52]. Wild type littermates
were maintained on the same diet. In some experiments,
8 week old mice were transferred onto solid mouse chow
instead of Peptamen, and survival was recorded. Mice
with apparent distress were sacrificed and survival on
chow was recorded as the following day. Male and female
mice were used at 6–16 weeks of age. Mice were kept in a
specific pathogen-free facility in barrier-top cages. All pro-
cedures were approved by the University of Kansas Medi-
cal Center IACUC.
Genetic background determination
The Genome Scanning Service of The Jackson Laboratory
(Bar Harbor, ME) was used to determine the contribu-
tions of C57Bl/6 and 129/Sv strains in the interbred mice.
Pieces of mouse tail were sent to The Jackson Laboratory
for simple sequence length polymorphism (SSLP) PCR
analysis with the DMit primers specific for B6 and 129
strain alleles http://www.jax.org. The SSLP panel consists
of 108 mapped markers designed to distinguish between
B6 and 129 strains. The markers are spaced 12–13 cM
apart and span the nineteen autosomes.BMC Genetics 2005, 6:29 http://www.biomedcentral.com/1471-2156/6/29
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Measurement of gene expression
Total RNA was extracted from the entire small intestine as
previously described [21]. Quantitative, real-time RT-PCR
was used to measure expression of specific genes using the
previously described primers [21]. Values were normal-
ized to GAPDH mRNA and expression of this housekeep-
ing gene is not altered in the CF mouse small intestine
[21]. Expression of the major intestinal mucin, Muc2, was
also measured using the forward (5'-GAC TTC GAT GGA
CAC TGC TC-3') and reverse (5'-CAC GGT GTT TAT CTA
CCA AC-3') primers.
Histology
The small intestine was flushed with phosphate buffered
saline and immersion fixed overnight in 4% paraformal-
dehyde. The tissues were then prepared for paraffin
embedding and sectioning by a commercial service
(HSRL, Woodstock, VA). Sections (5 µm) were stained
with periodic acid Schiff's (PAS) for neutral mucins.
Statistics
Gene expression and body weight data were compared by
ANOVA with a post-hoc Tukey's analysis (Systat software,
Chicago, IL). Survival data were analyzed by a log-rank
test for P  values (PEPI software, http://www.brixton
health.com/). The distributions of genotypes of pups sur-
viving to weaning from breeding Cftr(+/-) mice were
compared to that expected by Mendelian genetics using
Chi-square analysis. For all statistical tests, P < 0.05 was
considered significant.
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